Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma

Cancer Biology and Therapy

Volumn 11, Issue 4, 2011, Pages 401-409

  Deng, Hongxin ^a   Jiang, Qingyuan ^b   Yang, Yang ^a   Zhang, Shuang ^a   Ma, Yongping ^a   Xie, Gang ^a   Chen, Xiang ^a   Qian, Zhiyong ^a   Wen, Yanjun ^a   Li, Jiong ^a   Yang, Jinliang ^a   Chen, Lijuan ^a   Zhao, Xia ^a   Wei, Yuquan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Apoptosis; Cantionic liposome; Hepatocellular carcinoma; Polo like kinase 1 (Plk1); RNA interference; Short hairpin RNAs (shRNAs)

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; LIPOPLEX; PLASMID DNA; POLO LIKE KINASE 1; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CACHEXIA; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HEPG2; COMPETITIVE INHIBITION; CONTROLLED STUDY; DIARRHEA; DOWN REGULATION; DRUG FATALITY; EXPRESSION VECTOR; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOSOMAL DELIVERY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA VECTOR; TUMOR XENOGRAFT; WEIGHT REDUCTION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEP G2 CELLS; HUMANS; LIPOSOMES; MICE; MICE, NUDE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79951821312     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.4.14178     Document Type: Article

References (35)

1. Kensler TW, Qian GS, Chen JG, Groopman JD. Translational strategies for cancer prevention in liver. Nat Rev Cancer 2003; 3:321-9. (Pubitemid 37328852)
2. Akriviadis EA, Llovet JM, Efremidis SC, Shouval D, Canelo R, Ringe B, et al. Hepatocellular carcinoma. Br J Surg 1998; 85:1319-31. (Pubitemid 28468331)
3. Roxburgh P, Evans TR. Systemic therapy of hepatocellular carcinoma: are we making progress? Adv Ther 2008; 25:1089-104.
4. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6:321-30.
5. Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005; 24:267-76. (Pubitemid 40188607)
6. Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002; 29:354-8.
7. Studach LL, Rakotomalala L, Wang WH, Hullinger RL, Cairo S, Buendia MA, et al. Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression. Hepatology 2009; 50:414-23.
8. Chen XJ, Wu LM, Xu XB, Feng XW, Xie HY, Zhang M, et al. Expression and prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular carcinoma. Zhonghua Wai Ke Za Zhi 2007; 45:1354-8.
9. Yamada S, Ohira M, Horie H, Ando K, Takayasu H, Suzuki Y, et al. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 2004; 23:5901-11. (Pubitemid 39093534)
10. Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008; 26:5511-7.
11. Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005; 7:275-86. (Pubitemid 40568686)
12. Spankuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, Strebhardt K. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 2004; 96:862-72. (Pubitemid 38807607)
13. Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 2005; 115:978-85. (Pubitemid 40489402)
14. Spankuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, et al. Downregulation of Pololike kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 2006; 66:5836-46. (Pubitemid 43927138)
15. Zhou J, Gao Q, Chen G, Huang X, Lu Y, Li K, et al. Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability. Clin Cancer Res 2005; 11:8431-40. (Pubitemid 41746958)
16. Dykxhoorn DM, Lieberman J. The silent revolution: RNA interference as basic biology, research tool and therapeutic. Annu Rev Med 2005; 56:401-23. (Pubitemid 40299790)
17. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Ther 2006; 13:464-77.
18. Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther 2006; 13:644-70.
19. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9:347-51. (Pubitemid 36362792)
20. Ito I, Ji L, Tanaka F, Saito Y, Gopalan B, Branch CD, et al. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 2004; 11:733-9. (Pubitemid 39488471)
21. Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006; 26:2093-108. (Pubitemid 43346913)
22. Du XB, Lang JY, Xu JR, Lu Y, Wen YJ, Zhao JM, et al. Vesicular stomatitis virus matrix protein gene enhances the antitumor effects of radiation via induction of apoptosis. Apoptosis 2008; 13:1205-14.
23. Liu XQ, Erikson RL. Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. PNAS 2002; 99:8672-6. (Pubitemid 34693618)
24. Fumiko TM, Eri T, Nishida E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO reports 2002; 3:341-8. (Pubitemid 34467604)
25. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001; 61:2129-37. (Pubitemid 32692038)
26. He ZL, Zheng H, Lin H, Miao XY, Zhong DW. Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World J Gastroenterol 2009; 15:4177-82.
27. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002; 94:1863-77. (Pubitemid 36104631)
28. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20:1006-10.
29. Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J, et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296:497. (Pubitemid 34408663)
30. Marshall E. Gene therapy. Second child in French trial is found to have leukemia. Science 2003; 299:320.
31. Dass CR, Choong PF. Selective gene delivery for cancer therapy using cationic liposomes: in vivo proof of applicability. J Control Release 2006; 113:155-63. (Pubitemid 43928149)
32. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55:3752-6.
33. Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998; 101:1401-13. (Pubitemid 28166838)
34. Tousignant JD, Gates AL, Ingram LA, Johnson CL, Nietupski JB, Cheng SH, et al. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum Gene Ther 2000; 11:2493-513.
35. Loisel S, Le Gall C, Doucet L, Ferec C, Floch V. Contribution of plasmid DNA to hepatotoxicity after systemic administration of lipoplexes. Hum Gene Ther 2001; 12:685-96. (Pubitemid 32506946)